HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Serotonin Syndrome (Syndrome, Serotonin)

An adverse drug interaction characterized by altered mental status, autonomic dysfunction, and neuromuscular abnormalities. It is most frequently caused by use of both serotonin reuptake inhibitors and monoamine oxidase inhibitors, leading to excess serotonin availability in the CNS at the serotonin 1A receptor.
Also Known As:
Syndrome, Serotonin; Serotonin Syndromes; Syndromes, Serotonin
Networked: 714 relevant articles (9 outcomes, 22 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Hepatitis
2. Tremor (Tremors)
3. Seizures (Seizure)
4. Parkinson Disease (Parkinson's Disease)
5. Lethargy

Experts

1. Nisijima, Koichi: 7 articles (12/2015 - 07/2003)
2. Shioda, Katsutoshi: 6 articles (10/2012 - 07/2003)
3. Tao, Rui: 5 articles (04/2015 - 10/2010)
4. Kato, Satoshi: 5 articles (10/2012 - 07/2003)
5. Ma, Zhiyuan: 4 articles (04/2015 - 10/2010)
6. Fox, Meredith A: 4 articles (11/2013 - 10/2007)
7. Tepper, Stewart J: 4 articles (02/2012 - 02/2007)
8. Murphy, Dennis L: 4 articles (09/2009 - 10/2007)
9. Isbister, Geoffrey K: 4 articles (09/2007 - 10/2003)
10. Fink, Heidrun: 3 articles (01/2015 - 02/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Serotonin Syndrome:
1. Cyproheptadine (Periactin)FDA Link
2. DexmedetomidineFDA Link
3. Antidepressive Agents (Antidepressants)IBA
4. N-Methyl-3,4-methylenedioxyamphetamine (MDMA)IBA
5. BenzodiazepinesIBA
6. Chlorpromazine (Thorazine)FDA Link
7. 5-HT2C Serotonin ReceptorIBA
8. BPC 157IBA
04/11/2005 - "Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats."
04/11/2005 - "Thereby, in severe serotonin syndrome, gastric pentadecapeptide BPC 157 (alone, no behavioral or temperature effect) has a beneficial activity, which is likely, particular, and mostly related to a rather specific counteraction of 5-HT2A receptors phenomena."
04/11/2005 - "Indicatively, severe serotonin syndrome in pargyline + L-tryptophan rats is considerably inhibited even by lower pentadecapeptide BPC 157 doses regimens (particularly disturbances such as hyperthermia and wet dog shake thought to be related to stimulation of 5-HT2A receptors), while the highest pentadecapeptide dose counteracts mild disturbances present in pargyline rats (mild hypothermia, feeble hind limbs abduction). "
04/11/2005 - "In all experiments, gastric pentadecapeptide BPC 157 contrasts with serotonin-syndrome either (i) presentation (i.e., particularly counteracted) or (ii) initiation (i.e., neither a serotonin substrate (counteraction of pargyline), nor an inductor for serotonin syndrome (no influence on L-tryptophan challenge)). "
04/11/2005 - "Thereby, we investigate this peptide (10 microg, 10 ng, 10 pg/kg i.p.) in (i) full serotonin syndrome in rat combining pargyline (irreversible MAO-inhibition; 75 mg/kg i.p.) and subsequent L-tryptophan (5-HT precursor; 100 mg/kg i.p.; BPC 157 as a co-treatment), or (ii, iii) using pargyline or L-tryptophan given separately, as a serotonin-substrate with (ii) pargyline (BPC 157 as a 15-min posttreatment) or as a potential serotonin syndrome inductor with (iii) L-tryptophan (BPC 157 as a 15 min-pretreatment). "
9. EVAC protocol (CAVE)IBA
10. Serotonin (5 Hydroxytryptamine)IBA

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Polypharmacy
3. Critical Care
4. Intensive Care (Surgical Intensive Care)
5. Parathyroidectomy